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ExtEndEd rEport
Risankizumab, an IL-23 inhibitor, for ankylosing 
spondylitis: results of a randomised, double-blind, 
placebo-controlled, proof-of-concept, dose-finding 
phase 2 study
dominique Baeten,1 Mikkel Østergaard,2,3 James Cheng-Chung Wei,4,5 
Joachim Sieper,6 pentti Järvinen,7 Lai-Shan tam,8 Carlo Salvarani,9,10 tae-Hwan Kim,11 
Alan Solinger,12 Yakov datsenko,13 Chandrasena pamulapati,12 Sudha Visvanathan,12 
david B Hall,12 Stella Aslanyan,12 paul Scholl,12 Steven J padula14
AbstrACt
Objectives to evaluate the efficacy and safety of 
risankizumab, a humanised monoclonal antibody 
targeting the p19 subunit of interleukin-23 (IL-23), in 
patients with active ankylosing spondylitis (AS).
Methods A total of 159 patients with biological-naïve 
AS, with active disease (Bath Ankylosing Spondylitis 
disease Activity Index score of ≥4), were randomised 
(1:1:1:1) to risankizumab (18 mg single dose, 90 mg or 
180 mg at day 1 and weeks 8, 16 and 24) or placebo 
over a 24-week blinded period. the primary outcome was 
a 40% improvement in Assessment in Spondylo Arthritis 
International Society (ASAS40) at week 12. Safety was 
assessed in patients who received at least one dose of 
study drug.
results At week 12, ASAS40 response rates were 
25.5%, 20.5% and 15.0% in the 18 mg, 90 mg and 
180 mg risankizumab groups, respectively, compared 
with 17.5% in the placebo group. the estimated 
difference in proportion between the 180 mg 
risankizumab and placebo groups (primary endpoint) 
was –2.5% (95% CI –21.8 to 17.0; p=0.42). rates of 
adverse events were similar in all treatment groups.
Conclusions treatment with risankizumab did not meet 
the study primary endpoint and showed no evidence 
of clinically meaningful improvements compared with 
placebo in patients with active AS, suggesting that IL-23 
may not be a relevant driver of disease pathogenesis and 
symptoms in AS.
trial registration number nCt02047110; pre-results.
IntrOduCtIOn
Ankylosing spondylitis (AS) is a chronic inflamma-
tory rheumatic disease that predominantly affects 
the axial skeleton, leading to back pain, progressive 
structural and functional impairment and reduced 
quality of life.1 AS is generally unresponsive to 
conventional disease-modifying antirheumatic 
drugs (DMARDs), and systemic therapy for AS 
consists of non-steroidal anti-inflammatory drugs 
(NSAIDs), tumour necrosis factor inhibitors and, 
more recently, the interleukin (IL) 17A (IL-17A) 
inhibitor secukinumab.2–4 
Several lines of evidence have identified IL-23 as 
a promising therapeutic target in AS.5 At the genetic 
level, case–control genome-wide association studies 
have demonstrated that IL-23 receptor (IL-23R) 
polymorphisms are associated with an increased 
risk of developing AS.6 7 In addition, a protective 
effect of the IL-23RR381Q polymorphism is observed 
in AS.8 Increased numbers of IL-23-producing 
cells have been found in facet joints of patients 
with AS,9 while the number of IL-23-responsive 
T helper (Th) 22 (Th22), Th17 and gamma/delta 
T cells are elevated in blood from patients with 
AS.10 11 Stimulation of peripheral blood mono-
nuclear cells isolated from patients with AS leads 
to enhanced IL-23 production versus controls.12 
Finally, a potential role for the IL-23 pathway in 
driving entheseal inflammation and bone formation 
responses in AS has also been highlighted in murine 
models of spondyloarthritis.13 14 IL-23 is a key 
driver in the induction and maintenance of Th17 
cells.15 The recent approval of the IL-17A inhibitor, 
secukinumab, for the treatment of AS, supported 
the clinical hypothesis that direct and specific inhi-
bition of IL-23 would be of therapeutic benefit to 
patients with AS.2 16 17
Risankizumab (BI 655066/ABBV-066) is a 
humanised, immunoglobulin G1 monoclonal anti-
body that selectively inhibits IL-23 by specifically 
targeting the p19 subunit18 and has shown efficacy 
in psoriasis, psoriatic arthritis (PsA) and Crohn’s 
disease.19–22 This proof-of-concept, dose-ranging 
study assessed the efficacy and safety of risanki-
zumab in patients with active AS.
MethOds
study design
This phase 2, randomised, placebo-con-
trolled, double-blind study was conducted at 
47 centres across North America, Europe and 
East Asia between March and December 2014. 
Patients were randomly assigned (by interac-
tive response system) in a 1:1:1:1 ratio to one 
of three regimens of risankizumab (18 mg single 
dose, 90 mg or 180 mg at day 1 and weeks 8, 
16 and 24) or placebo (figure 1A). The doses 
selected were informed by a phase 1 study in 
psoriasis and included a 10-fold dose range 
of risankizumab with a single administration 
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at the low dose (18 mg) that was expected to be subthera-
peutic.19 The study comprised a 24-week blinded treat-
ment period, a potential escape treatment period from 
week 16 up to week 40 and a 24-week open-label exten-
sion period (not reported due to small sample size). Each 
treatment period had a 24-week follow-up (figure 1B). At 
week 16, escape treatment with 180 mg risankizumab was 
available for patients not achieving a 20% improvement 
in Assessment in SpondyloArthritis International Society 
(ASAS20) at week 12.
Amendments to the protocol can be found in the online 
supplementary materials. All authors approved the manuscript 
for submission and vouch for completeness of the data and the 
fidelity of the study to the protocol.
Patients
Patients aged 18–70 years were eligible if they had definite 
AS (1984 modified New York criteria23 and local X-ray eval-
uation), active disease defined as a Bath AS Disease Activity 
Index (BASDAI) score of ≥4,24 including a value ≥4 for 
Figure 1 Overview of study design and patient disposition. Overview of treatment and observation periods including escape and open-label 
extension phases (panel A); patients were randomised 1:1:1:1 to one of three regimens of risankizumab (18 mg single dose, 90 mg or 180 mg at   
day 1 and weeks 8, 16 and 24) or placebo; patients without ASAS20 response at week 12 received escape treatment; patients with a flare of disease 
activity within 24 weeks of the last double-blind treatment entered the open-label extension. Arrows represent treatment administration. *Patients 
received 18 mg single dose at day 1 followed by placebo at weeks 8, 16 and 24. Trial profile (panel B). AE, adverse event; ASAS20, 20% improvement 
in Assessment in SpondyloArthritis International Society; DB, double blind; FU, follow-up; OLE, open-label extension; PV, protocol violation.
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overall level of AS neck, back or hip pain, and documented 
inadequate response (30 days of optimal daily doses with ≥2 
NSAIDs) or intolerance to NSAIDs. Patients previously treated 
with any biological for AS were excluded, and other biologicals 
were not permitted during the study. From 2 weeks prior to 
randomisation and up to 12 weeks of treatment, conventional 
DMARDs, low-dose systemic steroids (equivalent to ≤10 mg 
prednisolone/day), NSAIDs or analgesics at stable doses were 
permitted under the direction of the investigator. See online 
supplementary material for full inclusion/exclusion criteria. 
All patients provided written informed consent.
Assessments
The primary endpoint was the proportion of patients achieving 
an ASAS40 response at week 12. The key secondary endpoint 
was the change from baseline in the assessment of disease 
activity based on the AS Disease Activity Score-C reactive 
protein (ASDAS-CRP) at week 12. All secondary and further 
endpoints are listed in the online supplementary material. 
Of these, MRI assessments of the spine and sacroiliac (SI) 
joints, using the SpondyloArthritis Research Consortium of 
Canada (SPARCC) MRI indices for scoring inflammation in 
the SI joint25 and spine,26 were performed pretreatment and 
post-treatment (at week 24 for patients completing 24-week 
blinded treatment and at week 12 for patients starting escape 
treatment) within a subset of patients (see online supplemen-
tary material for methodology).
Safety endpoints included adverse events (AEs), serious AEs 
(SAEs), discontinuation of therapy because of AEs, local tolera-
bility, changes in vital signs and physical examination and labo-
ratory assessments.
Additionally, the IL-23/Th17 pathway biomarker β-defensin 2 
and bone remodelling biomarkers associated with AS were eval-
uated in sera pretreatment and post-treatment at baseline and 
at week 12. Plasma samples for pharmacokinetic (PK) analysis 
and immunogenicity assessments were collected at prespecified 
visits (see online supplementary material for methodologies). A 
post hoc analysis of change from baseline in C reactive protein 
(CRP) level was also performed.
statistical analysis
Sample size was determined based on one-sided comparison 
between the 180 mg risankizumab dose and placebo using 
Fisher’s exact conditional test, consistent with the one-sided 
alternate hypothesis of a week 12 ASAS40 response rate 
of 43% with 180 mg risankizumab and a rate of 13% with 
placebo; randomisation of 160 patients (40 per study group) 
was estimated to provide 89% power using a one-sided test 
of 0.05 significance. The hierarchical inference strategy 
protects against type 1 error in other comparisons and other 
endpoints. Analyses were conducted with all randomised 
patients who received at least one dose of trial medication 
(full analysis). The Suissa-Shuster unconditional exact test 
was used to test the difference in the proportion of patients 
achieving the primary endpoint between treatment groups per 
intention-to-treat principles. The CI for the difference in the 
proportion between the treatment groups was obtained by 
the Clopper-Pearson method. To control the type I error rate, 
endpoints were tested in a hierarchical fixed sequence, starting 
with a primary endpoint comparison between the 180 mg 
risankizumab group versus placebo, with a 5% (one-sided) 
significance level. Because the primary analysis failed to 
show superiority of 180 mg risankizumab over placebo, all 
remaining analyses were exploratory with nominal p values. 
For any missing week 12 ASAS40 assessment, non-responder 
imputation was used. Patients receiving prohibited concom-
itant medication for AS prior to week 12 were considered 
as treatment failures. Statistical analyses for secondary and 
further endpoints are described in the online supplementary 
material.
results
study population and patient disposition
Of the 219 patients screened, 159 underwent randomisation: 
40 patients were assigned to 18 mg risankizumab, 39 patients 
to 90 mg risankizumab, 40 patients to 180 mg risankizumab and 
40 patients to placebo. Up to week 12, 12 patients discontinued 
(ie, did not receive an injection at week 8); there was no imbal-
ance in the frequency of premature discontinuation between 
risankizumab groups. One patient (placebo) discontinued trial 
medication due to worsening of AS prior to week 12 (figure 1B). 
A total of 51 patients fulfilled the ASAS20 response criteria at 
week 12 and continued treatment to week 24, and 96 patients 
were switched to escape treatment.
Demographic and baseline characteristics were balanced 
across study groups, with some variation related to the 
limited sample size (table 1). In particular, a lower number 
of HLA-B27-positive patients were randomised to the placebo 
group, most likely reflecting the higher number of Asian 
patients in the placebo group compared with risankizumab 
groups. Overall, the baseline disease activity and CRP levels of 
patients in this study were similar or somewhat less severe to 
those of patients in recent AS clinical trials.2 16
efficacy
The primary endpoint, ASAS40 response at week 12, was not 
met. ASAS40 response at week 12 was achieved by 25%, 21% 
and 15% of patients in the 18 mg, 90 mg and 180 mg risanki-
zumab groups, respectively, compared with 18% in the placebo 
group. The estimated difference in the proportion of ASAS40 
responders between the 180 mg risankizumab group and placebo 
(primary endpoint) was –2.5% (95% CI –21.8 to 17.0; p=0.42) 
and 7.5% (95% CI –12.1 to 26.6; p=0.27) and 3.0% (95% CI 
–15.9 to 20.8; p=0.41) between the 18 mg and 90 mg risanki-
zumab groups versus placebo, respectively (figure 2A). The 
prolongation of risankizumab treatment for up to 40 weeks by 
patients receiving escape treatment (180 mg risankizumab) did 
not substantially improve ASAS40 attainment rates.
ASAS20 response at week 12 was achieved by 45%, 33% and 
30% of patients in the 18 mg, 90 mg and 180 mg risankizumab 
groups, respectively, compared with 20% in the placebo group 
(figure 2B). ASAS 5/6 response at week 12 was achieved by 
20%, 23% and 15% of patients in the 18 mg, 90 mg and 180 mg 
risankizumab groups, respectively, compared with 5% in the 
placebo group (figure 2C). Partial remission (ASAS criteria) at 
week 12 was achieved by 3%, 3% and 10% of patients in the 
18 mg, 90 mg and 180 mg risankizumab groups, respectively, 
compared with 3% in the placebo group (figure 2D).
Median change (IQRs) from baseline in ASDAS-CRP at 
week 12 were –0.7 (–1.3 to –0.2), –0.6 (–1.2 to 0.0) and –0.7 
(–1.1 to –0.3) for the 18 mg, 90 mg and 180 mg risankizumab 
groups, respectively, compared with –0.3 (–1.0 to 0.2) for the 
placebo group (figure 3A). A dose-dependent reduction in 
CRP was observed with risankizumab compared with placebo 
at week 12 (figure 3B). For the BASDAI score (figure 3C) 
and other efficacy endpoints (Bath Ankylosing Spondylitis 
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Functional Index, Bath Ankylosing Spondylitis Metrology 
Index, tender joint count, swollen joint count and Maastrich 
Ankylosing Spondylitis Enthesitis Score), there were no mean-
ingful changes over time between the risankizumab groups and 
placebo (online supplementary table S8).
Only ASAS20 responders at week 12 (32%) continued blinded 
treatment up to week 24 (94% completing blinded treatment; 
figure 1), and most ASAS40 responders at week 12 (n=31) 
remained responders up to week 24 (n=29).
Subgroup analyses of ASAS40 response at week 12 by base-
line CRP level, geographic region or morning stiffness did not 
reveal a higher ASAS40 response for any risankizumab group 
compared with placebo (online supplementary table S9).
Findings from the MRI analysis were generally consistent 
with clinical effects (online supplementary table S10 and figure 
S1). In patients who continued treatment to week 24, risanki-
zumab had no effect on SPARCC SI joint score compared 
with placebo (online supplementary table S10) but improved 
table 1 Baseline demographics and clinical characteristics
Placebo risankizumab
(n=40) 18 mg (n=40) 90 mg (n=39) 180 mg (n=40)
Age, years (SD) 37.6 (11.0) 38.0 (11.1) 39.5 (10.8) 40.6 (11.9)
Male, n (%) 25 (63) 28 (70) 30 (77) 30 (75)
Race, n (%)
  White 19 (48) 26 (65) 28 (72) 22 (55)
  Asian 20 (50) 13 (33) 11 (28) 17 (43)
  Other* 1 (3) 1 (3) 0 1 (3)
Geographic region, n (%)
  Europe 18 (45.0) 23 (57.5) 24 (61.5) 20 (50.0)
  Asia 20 (50.0) 13 (32.5) 11 (28.2) 17 (42.5)
  USA 2 (5.0) 4 (10.0) 4 (10.3) 3 (7.5)
BMI, kg/m2 (SD) 24.2 (4.3) 26.2 (5.3) 25.9 (4.6) 25.8 (4.5)
HLA-B27 status, n (%)
  Positive 26 (65) 30 (75) 30 (77) 34 (85)
  Missing 4 (10) 4 (10) 4 (10) 2 (5)
Duration of disease, years (SD) 8.1 (8.2) 7.4 (8.2) 6.6 (8.8) 10.2 (9.5)
ASAS core components on NRS† (SD)
  Patient global 7.2 (2.0) 7.2 (1.7) 6.5 (1.7) 6.8 (2.2)
  Inflammation 6.2 (2.2) 6.4 (2.0) 6.5 (1.8) 6.0 (2.2)
  Spinal pain 6.8 (2.0) 6.5 (1.8) 6.3 (1.8) 6.4 (1.9)
  Physical function 4.6 (2.3) 4.9 (2.1) 4.9 (1.9) 4.5 (2.6)
  ASDAS-CRP 3.5 (3.0, 4.3) 3.6 (2.9, 4.2) 3.5 (2.9, 4.0) 3.6 (2.8, 4.0)
  BASDAI 6.3 (5.1, 7.2) 6.4 (5.1, 7.1) 5.8 (4.8, 7.1) 6.1 (4.3, 7.4)
  BASMI 3.0 (1.0, 4.5) 2.0 (1.0, 3.0) 3.0 (1.0, 4.0) 3.0 (1.0, 5.0)
CRP level, mg/L
  <2.87 (ULN) 10 (25) 11 (27) 5 (13) 11 (27)
  ≥2.87 30 (75) 29 (73) 34 (87) 29 (73)
  ≥2.87 to <8 14 (35) 12 (30) 20 (26) 10 (25)
  ≥8 to ≤15 9 (23) 6 (15) 5 (13) 11 (28)
  >15 7 (18) 11 (28) 9 (23) 8 (20)
SPARCC SI joint, N median (IQR) 14 9 14 16
0.8 (0.0–4.0) 2.5 (2.0–15.5) 1.5 (0.0–8.5) 3.3 (0.8–7.3)
SPARCC total spine, N median (IQR) 14 9 14 16
11.3 (3.5–22.0) 9.0 (4.5–24.0) 11.3 (3.8–18.8) 8.3 (0.8–27.5)
Concomitant csDMARD‡ 20 (50.0) 8 (20.0) 8 (20.5) 20 (50.0)
Concomitant NSAIDs§ and/or paracetamol 36 (90.0) 35 (87.5) 34 (87.2) 33 (82.5)
Concomitant GCs 3 (7.5) 5 (12.5) 2 (5.1) 3 (7.5)
Data are mean (SD), n (%) or median (IQR).
*Other includes black or African-American and American Indian or Alaska Native.
†Patients assessment of ASAS core components on NRS (0–10): patient global is based on global AS disease activity; inflammation is based on the mean of BASDAI questions 5 
and 6 addressing the level of morning stiffness and duration; spinal pain is based on the mean of two questions; physical function is based on BASFI.
‡Concomitant csDMARDs include sulfasalazine, methotrexate, hydroxychloroquine and leflunomide.
§Concomitant NSAIDs include etoricoxib, celecoxib, meloxicam, diclofenac, diclofenac sodium, naproxen, ibuprofen, piroxicam, ketoprofen, indomethacin, aceclofenac, diclofenac 
resinate, etodolac, vimovo, acemetacin, morniflumate, naproxen sodium, phenylbutazone and sulindac.
AS, ankylosing spondylitis; ASAS, Assessment of SpondyloArthritis International Society; ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score-CRP; BASDAI, Bath Ankylosing 
Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; BMI, body mass index; CRP, 
C reactive protein; csDMARD, conventional synthetic disease-modifying antirheumatic drug; GC, glucocorticoid; HLA, human leucocyte antigen; NRS, numerical rating scale; 
NSAID, non-steroidal anti-inflammatory drug; SI, sacroiliac; SPARCC, SpondyloArthritis Research Consortium of Canada; ULN, upper limit of normal.
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Figure 2 Response rates for ASAS40, ASAS20, ASAS 5/6 and ASAS partial remission during double-blind and escape treatment and follow-up 
periods. Clinical response rates over time for double-blind and escape treatment periods. ASAS40 (panel A), ASAS20 (panel B), ASAS 5/6 (panel C)   
and partial remission (panel D). NRI was used for missing data. Number of patients entering the double-blind treatment were: placebo: n=40; 
18 mg risankizumab: n=40; 90 mg risankizumab: n=39; and 180 mg risankizumab: n=40. Patients entering escape treatment received 180 mg 
risankizumab; responses shown for the escape period are by the original randomised treatment (placebo: n=26; 18 mg risankizumab: n=21; 90 mg 
risankizumab: n=23; 180 mg risankizumab: n=26). Values for all data points are provided in online supplementary tables S1–S4. ASAS, Assessment in 
SpondyloArthritis International Society; NRI, non-responder imputation.
Figure 3 Change from baseline in ASDAS-CRP, CRP and BASDAI over time to week 12. Change from baseline in ASDAS-CRP (panel A), CRP (mg/L) 
(panel B) and BASDAI (panel C) over time to week 12. Median (IQR) changes are shown (observed). The values under each plot are the number of 
patients per treatment arm with a valid measurement at the specified time point. *P=0.0229 and p=0.0101 for median change in ASDAS-CRP for 
18 mg and 180 mg risankizumab, respectively, versus placebo at week 12. Values for all data points are provided in online supplementary   
tables S5–S7. ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score-CRP; BASDAI, Bath Ankylosing Spondylitis Disease Activity Score; CRP, 
C reactive protein.
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SPARCC total spine (median (IQR)) change from baseline in 
the 90 mg (–6.0 (–12.0 to –2.8); p=0.0046) and 180 mg (–3.8 
(–8.0 to 1.3); p<0.05) risankizumab groups, compared with 
placebo at week 24. For patients who switched to escape treat-
ment, there was no difference in change in SPARCC total spine 
or SI joint scores at week 12 or from weeks 12–24 between 
treatment groups (online supplementary table S10).
There were minimal differences between the changes from 
baseline in levels of β-defensin 2 and biomarkers of bone remod-
elling (dikkopf-1, sclerostin, BMP-7 and osteocalcin) in patients 
receiving risankizumab versus placebo over time. A heat map 
showing the percentage change from baseline to week 12 in 
biomarkers versus change in clinical and MRI parameters in 
ASAS20 responders and non-responders is provided in online 
supplementary figure 2.
safety
Up to week 16, the rate of AEs was comparable between the 
risankizumab groups and the placebo group. Most reported AEs 
were of mild or moderate intensity, and there were no reports of 
severe infections across all groups. Three patients in the placebo 
group had AEs leading to the premature discontinuation of trial 
medication. The frequency of investigator-defined drug-related 
AEs was low and comparable between the risankizumab and 
placebo groups (table 2). The most common AEs reported with 
risankizumab and/or placebo included nasopharyngitis, head-
ache and fatigue. Up to the end of the trial, the rate and profile 
of AEs in the risankizumab total group was consistent with the 
up to 16 weeks data in this trial and with other risankizumab 
trials (online supplementary table S11). All SAEs were deemed 
non-drug related by the investigator and were graded as serious 
due to the need for hospitalisation. Local tolerability issues at 
the injection site were uncommon and mostly mild, and no 
anaphylactic reactions or inflammatory bowel syndrome diag-
noses were reported.
Overall, PK parameters and the exposure (online supplemen-
tary table S12) of risankizumab in patients with AS were compa-
rable with patients with psoriasis treated with risankizumab in 
prior trials.19 20 Antidrug antibody (ADA) incidence was 14%, 
with 4% testing positive at baseline before treatment (pre-ex-
isting ADA) and only 3% testing positive in the neutralising 
antibody assay. In most patients, ADAs were transient and of 
low titre (≤16). These results were similar to those reported in 
patients with psoriasis in a previous trial.20 ADAs did not impact 
the exposure or safety of risankizumab.
dIsCussIOn
AS is a complex polygenic disease showing a genetic association 
with the IL-23 pathway.6 8 However, in this phase 2, proof-of-
concept study, a significant improvement in the proportion of 
patients achieving an ASAS40 response with risankizumab at 
week 12, compared with placebo, was not demonstrated. Longer 
treatment (up to 40 weeks, by patients receiving escape treat-
ment with 180 mg risankizumab) did not substantially improve 
ASAS40 attainment rates. The lack of efficacy was also confirmed 
by most secondary and other endpoints. While modest reductions 
of ASDAS-CRP were evident with risankizumab, a clinically rele-
vant change of ≥1.1 was not achieved.27 ASAS 5/6 at week 12 was 
the only secondary endpoint to demonstrate a higher response 
rate in each of the risankizumab treatment groups compared with 
placebo. The primary driver in both ASDAS-CRP and ASAS 5/6 
reductions was CRP, with minimal changes in other composite 
endpoint parameters. Findings from MRI analysis indicated a 
limited impact of risankizumab at week 24 on SPARCC total 
spine score in patients with a clinical response. Despite this, trial 
discontinuations due to lack of efficacy were low.
table 2 AEs summary up to 16 weeks
Aes, n (%)
Placebo risankizumab
(n=40) 18 mg (n=40) 90 mg (n=39) 180 mg (n=40)
Any AE 26 (65) 28 (70) 22 (56.4) 26 (65)
  Infections and infestations 13 (32.5) 16 (40) 11 (28.2) 10 (25)
  Musculoskeletal and connective tissue disorder 14 (35) 6 (15) 5 (12.8) 7 (17.5)
Severe AEs 1 (2.5) 1 (2.5) 1 (2.6) 0
Drug-related AEs 7 (17.5) 10 (25) 9 (23.1) 8 (20)
AEs leading to discontinuation 3 (7.5) 0 0 0
Serious infections 0 0 0 0
Serious AEs 2 (5) 0 2 (5.1) 1 (2.5)
Common AEs*
  Nasopharyngitis 3 (7.5) 6 (15) 4 (10.3) 10 (25)
  Influenza 1 (2.5) 2 (5) 2 (5.1) 4 (10)
  Sinusitis 1 (2.5) 0 2 (5.1) 1 (2.5)
  Arthralgia 4 (10) 0 2 (5.1) 1 (2.5)
  Back pain 2 (5) 3 (7.5) 1 (2.6) 2 (5.0)
  Fatigue 2 (5) 2 (5) 1 (2.6) 4 (10)
  Diarrhoea 0 2 (5) 1 (2.6) 3 (7.5)
  Headache 3 (7.5) 5 (12.5) 3 (7.7) 4 (10)
  Dizziness 0 0 2 (5.1) 1 (2.5)
  Increased blood CPK 3 (7.5) 1 (2.5) 2 (5.1) 1 (2.5)
  Eczema 1 (2.5) 0 2 (5.1) 0
  Renal colic 0 0 2 (5.1) 0
AEs were coded using MedDRA V.19.0. The severity of AEs was graded according to RCTC V.2.0.
*Common AEs were reported in at least 5% of patients in any treatment group.
AE, adverse event; CPK, creatine phosphokinase; MedDRA, Medical Dictionary for Regulatory Activities; RCTC, Rheumatology Common Toxicity Criteria.
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Risankizumab was generally well tolerated in this study, and 
there were no new or unexpected safety signals identified.19–22
Findings of this study are in contrast to those reported for 
secukinumab, an IL-17A inhibitor that demonstrated efficacy 
in patients with AS.2 16 17 In an open-label trial, ustekinumab 
(an IL-12/23 inhibitor) showed efficacy in 20 patients with AS 
through 28 weeks; however, recently, phase 3 trials in AS and 
non-radiographic axial spondyloarthritis were terminated for 
not meeting key efficacy endpoints ( ClinicalTrials. gov identifiers: 
NCT02438787 and NCT02407223).28 The failure of risanki-
zumab in this study was unexpected, and the underlying reasons 
remain unclear. Theoretically, it is possible that risankizumab 
may not have sufficiently blocked levels of IL-23 in the target 
organ (ie, the spine and SI joints). However, this is unlikely for 
the following reasons: risankizumab has shown proof-of-con-
cept in psoriasis,19 20 PsA22 and Crohn’s disease;21 the observed 
PK exposure levels were consistent with effective exposures in 
psoriasis; risankizumab had a dose-dependent effect on CRP; 
and that an evident improvement in SPARCC spine score in the 
90 mg and 180 mg treatment groups was seen in patients who 
had remained within 24-week blinded treatment in this study. 
Enrolment criteria in this study excluded patients with concom-
itant inflammatory bowel disease or PsA; however, patients with 
concomitant psoriasis were permitted, but unfortunately infor-
mation on this comorbidity was not collected systematically, and 
thus we were unable to assess whether there were any improve-
ments in psoriatic lesions, as evidenced in previous studies of 
risankizumab in patients with psoriasis.
Alternatively, risankizumab may not have sufficiently 
blocked all relevant sources of IL-17 production. Previously, 
risankizumab has been shown to reduce the levels of IL-17A, 
IL-23A and associated transcripts in lesional skin of patients 
with psoriasis.19 Although it is well characterised that one 
function of IL-23 is the induction and maintenance of Th17 
cells,15 it is likely that IL-23-independent sources of IL-17 are 
still active, such as IL-17-secreting mast cells and mucosal- 
associated invariant T cells.29 In addition, in in vivo autoim-
mune mouse models, dual inhibition of IL-17 and IL-23 was 
more efficacious in reducing disease than targeting either cyto-
kine alone,30 confirming that the relationship between IL-23 
and IL-17 is not linear. Discordant effects of IL-17 and IL-23 
inhibition were previously observed in Crohn’s disease, where 
a lack of clinical efficacy of IL-17 inhibitors and even disease 
exacerbation and elevated inflammatory markers (including 
serum CRP and faecal calprotectin) were reported,15 whereas 
IL-23 inhibition has shown proof-of-concept in Crohn’s 
disease.21
The results of this study challenge the notion that IL-23 is a 
relevant driver of AS disease pathogenesis and symptoms. This 
is further supported by analyses showing no overall differences 
in change in levels of an antimicrobial peptide and IL-23/Th17 
pathway biomarker and select biomarkers of bone remodelling 
in patients receiving risankizumab versus placebo. The role of 
changes in β-defensin 2 in disease processes occurring in AS 
is less understood compared with psoriasis,20 21 but the results 
from the current study suggest there may be differences between 
IL-23/Th17 pathway biomarkers associated with psoriasis and 
those associated with AS.
A possible limitation of this study is that the design did not 
include a loading dose, as has been included in some clinical 
studies of biological agents in AS and in phase 2 studies for 
risankizumab in psoriasis (treatment at weeks 0, 4 and 16)20 
and Crohn’s disease (induction dosing every 4 weeks intrave-
nously for 12 weeks);21 therefore, the study design might have 
potentially contributed to the negative results. However, because 
there was no convincing evidence for a dose response in this 
study, and a single dose of 18 mg risankizumab has demonstrated 
efficacy in a psoriasis phase 2 trial,20 it is unlikely that a loading 
dose would have improved the treatment response in AS. Studies 
with secukinumab have also indicated that a loading dose is 
not required, thus leading it to be optional in the secukinumab 
label.2 31 Another limitation of the study design was that there 
was no comparator arm in the escape group that received four 
additional doses of open-label 180 mg risankizumab, making 
the efficacy data for the 96 patients in this group difficult to 
interpret.
In this proof-of-concept study, risankizumab was not effective 
in reducing the signs and symptoms of AS. The lack of efficacy 
of this IL-23 inhibitor at subcutaneous doses previously shown 
to be highly effective in psoriasis suggests that, despite a genetic 
association with the IL-23 pathway, IL-23 may not be a relevant 
driver of disease pathogenesis and symptoms in AS.
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